Illumina (NASDAQ:ILMN) Upgraded at Daiwa America

Daiwa America upgraded shares of Illumina (NASDAQ:ILMN) to a strong-buy rating in a research note released on Friday morning, Zacks.com reports.

Several other analysts have also recently weighed in on the stock. TD Cowen upgraded shares of Illumina from a hold rating to a buy rating and lifted their price objective for the stock from $126.00 to $144.00 in a research note on Wednesday, August 14th. JPMorgan Chase & Co. decreased their target price on shares of Illumina from $130.00 to $125.00 and set a neutral rating on the stock in a research report on Wednesday, August 7th. Barclays upgraded shares of Illumina from an underweight rating to an equal weight rating and set a $125.00 target price on the stock in a research report on Wednesday, August 14th. UBS Group increased their target price on shares of Illumina from $131.00 to $133.00 and gave the stock a neutral rating in a research report on Wednesday, August 7th. Finally, Royal Bank of Canada restated an outperform rating and set a $242.00 target price on shares of Illumina in a research report on Wednesday, August 14th. One analyst has rated the stock with a sell rating, nine have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Illumina has a consensus rating of Moderate Buy and a consensus price target of $151.10.

Illumina Price Performance

Illumina stock opened at $135.90 on Friday. The company has a market capitalization of $21.65 billion, a price-to-earnings ratio of -16.67 and a beta of 1.15. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.26. Illumina has a 12 month low of $89.00 and a 12 month high of $171.50. The stock’s 50 day moving average is $115.20 and its 200-day moving average is $122.17.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, August 6th. The life sciences company reported $0.36 EPS for the quarter, beating analysts’ consensus estimates of $0.12 by $0.24. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The firm had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.09 billion. During the same period in the prior year, the firm posted $0.32 EPS. The company’s revenue for the quarter was down 5.4% on a year-over-year basis. Equities research analysts expect that Illumina will post 1.5 EPS for the current year.

Hedge Funds Weigh In On Illumina

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bouvel Investment Partners LLC lifted its stake in Illumina by 1.3% in the 1st quarter. Bouvel Investment Partners LLC now owns 6,547 shares of the life sciences company’s stock valued at $899,000 after purchasing an additional 84 shares during the last quarter. UMB Bank n.a. raised its stake in shares of Illumina by 7.0% during the second quarter. UMB Bank n.a. now owns 1,341 shares of the life sciences company’s stock valued at $140,000 after acquiring an additional 88 shares during the last quarter. STF Management LP raised its stake in shares of Illumina by 3.5% during the fourth quarter. STF Management LP now owns 2,644 shares of the life sciences company’s stock valued at $368,000 after acquiring an additional 90 shares during the last quarter. Global Retirement Partners LLC raised its stake in shares of Illumina by 12.3% during the first quarter. Global Retirement Partners LLC now owns 856 shares of the life sciences company’s stock valued at $118,000 after acquiring an additional 94 shares during the last quarter. Finally, Gulf International Bank UK Ltd raised its stake in shares of Illumina by 0.7% during the first quarter. Gulf International Bank UK Ltd now owns 13,562 shares of the life sciences company’s stock valued at $1,862,000 after acquiring an additional 98 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.